Skip to main content
SpringerLink
Log in

Three new active cisplatin‐containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We designed three new four–drug cisplatin–containing combinations and evaluated their activity in a randomized phase II study including patients with locally advanced (stage III) and locally recurrent breast carcinoma.

All combinations included methotrexate (M) on day 1 and cisplatin (P) on day 2 (MVAC–like combinations) and differed from one another by the addition of Epirubicin (Epi), Vincristine (V), Etoposide (E), Mitomycin (Mi). Based on the administered agents, they were named MPEMi, MPEpiE, MPEpiV. The combinations were randomly assigned to 101 patients, 57 with locally advanced and 44 with locally recurrent breast carcinoma. Response was evaluated after 4 cycles.

The complete response (CR) rates were 7 and 43 and the CR plus partial response (PR) rates were 84 and 89 in locally advanced and in locally recurrent disease, respectively. In locally advanced disease, a pathologic CR (pCR) was assessed in seven of 57 patients (12). There were no significant differences among the three combinations. The toxicities were at times severe, but generally tolerable, as demonstrated by the high cumulative doses of the drugs received by the patients.

In conclusion, these three innovative chemotherapy regimens induced high CR plus PR rates in the neoadjuvant treatment of stage III and of locally recurrent breast carcinoma, and a high rate of pCR in stage III disease. These regimens warrant testing in phase III trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wittes RE, Adrianza ME, Parsons B, Felix J, Marsoni S: Compilation of phase II results with single antineoplastic agents. Cancer Treat Symposia 4: 1–477, 1985

    Google Scholar 

  2. Kolaric K, Roth A: Phase II clinical trial of cisdichlorodiammine platinum (Cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11: 108–112, 1983

    Google Scholar 

  3. Sledge GW Jr., Loehrer PJ Sr., Roth BJ, Einhom LH: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6: 1811–1814, 1988

    Google Scholar 

  4. Peters WP, Jones RB, Vredenburgh J, Shpall EJ, Hussein A, Elkordy M, Rubin P, Ross M, Berry D: A large prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). 'Abstract'. Proceed ASCO 15: 149, 1996

    Google Scholar 

  5. Cocconi G, Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, Colozza MA, De Lisi V, Lottici R, Mosconi AM, Passalacqua R, Tonato M: Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 9: 664–669, 1991

    Google Scholar 

  6. Roth BJ, Sledge GW Jr., Williams SD, Meyer SC, Ansari R, Fisher WB: Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group. Cancer 68: 248–252, 1991

    Google Scholar 

  7. Bisagni G, Cocconi G, Ceci G, De Lisi V, Di Blasio B, Lottici R, Passalacqua R, Finardi C: M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma. A phase II study. Ann Oncol 5: 93–94, 1994

    Google Scholar 

  8. Langer CJ, Catalano R, Weiner LM, Scher R, Bagchi P, Saren B, Comis RL: Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in advanced, measurable breast carcinoma. Cancer Investigation 13: 150–159, 1995

    Google Scholar 

  9. American Joint Committee on Cancer: Manual for Staging of Cancer. Fourth edn J.B. Lippincott Company, Philadelphia, 1992, pp. 149–154

  10. Recth A, Hayes DF: Specific sites and emergencies: local recurrence. In: Harris JR, Helmann S, Henderson IC et al. (eds). Breast Disease (2nd edn). Lippincott Philadelphia, PA, 1991, pp 527–540

  11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mc-Fadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655, 1982

    Google Scholar 

  12. Miller AB, Hoogstraten B, Staquet M, Winker A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981

    Google Scholar 

  13. Cocconi G, Di Blasio B, Alberti G, Bisagni G, Botti E, Peracchia G: Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat 4: 309–313, 1984

    Google Scholar 

  14. Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CWL, Spiro SG, Gregory WM, Ledermann JA, Souhami RL, Harper PG: Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 12: 77–82, 1994

    Google Scholar 

  15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Ass 53: 457–481, 1958

    Google Scholar 

  16. Bartelink H, Rubens RD, van der Schueren E and Sylvester R: Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol 15: 207–215, 1997

    Google Scholar 

  17. Booser DJ, Hortobagyi GN: Treatment of locally advanced breast cancer. Seminars in Oncology 19: 278–285, 1992

    Google Scholar 

  18. Valagussa P, Zambetti M, Bonadonna G, Zucali R, Mezzanotte G, Veronesi U: Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat 15: 137–147, 1990

    Google Scholar 

  19. Patanaphan V, Salazar OM, Poussin-Rosillo H: Prognosticators in recurrent breast cancer: a 15-year experience with irradiation. Cancer 54: 228–234, 1984.

    Google Scholar 

  20. Blumenschein GR, Pinnamanemi K, Budzar AU, Hortobagyi GN, Yap H, Montague ED, Ames FC: Combined regional and systemic therapy in breast cancer patients with an isolated metastases with or without chemotherapy. In: Orlando. Jones SE, Salmon SE (eds), Adjuvant Therapy of Cancer IV. Grune and Stratton, New York, 1984, pp 311–318

    Google Scholar 

  21. Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi WF, Thürlimann B, Cavalli F, Obrecht JP, Leyvraz S, Alberto P, Adam H, Varini M, Loehnert T, Senn HJ, Metzger U, Brunner K: First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol 12: 2071–2077, 1994

    Google Scholar 

  22. Goldhirsh A, Gelber RD and Castiglione M: Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 6: 89–97, 1988

    Google Scholar 

  23. Fisher B, Brown A, Mamounas E, Wieand S, Fisher E, Robidoux A, Margolese R, Cruz A, Wickerham DL, Wolmark N: Effect of preoperative therapy for primary breast cancer on local-regional disease, disease-free survival and survival: results from NSABP B-18. 'Abstract'. Proceed ASCO 16: 127a, 1997

    Google Scholar 

  24. De Lena M, Varini M, Zucali R, Rovini D, Viganotti G, Valagussa P, Veronesi U, Bonadonna G: Multimodal treatment for locally advanced breast cancer. Cancer Clin Trials 4: 229–236, 1981

    Google Scholar 

  25. Perloff M, Lesnick GJ, Korzun A, Chu F, Holland JF, Thirlwell MP, Ellison RR, Carey RW, Leone L, Weinberg V, Rice MA, Wood WC: Combination chemotherapy withmastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 6: 261–269, 1988

    Google Scholar 

  26. Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN: Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clinical Cancer Research 3: 1565–1569, 1997

    Google Scholar 

  27. Hortobagyi GN, Ames FC, Budzar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, McBride CM, Martin RG, Montague E: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507–2516, 1988

    Google Scholar 

  28. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, Steiberg SM, Lippman ME: Neoadjuvant chemotherapy in the combined modality approach of locally advanced non metastatic breast cancer. Cancer Res 47: 3889–3894, 1987

    Google Scholar 

  29. Hoogstraten B, Gad-el-Mawla N, Maloney TR, Fletcher WS, Vaughn CB, Tranum BL, Athens JW, Costanzi JJ, Foulkes M: Combined modality therapy for first recurrence of breast cancer: a Southwest Oncology Group Study. Cancer 54: 2248–2256, 1984.

    Google Scholar 

  30. Piccart MJ, De Valeriola D, Paridaens R, Balikdjian D, Mattheiem WH, Loriaux C, Arrigo C, Cantraine F, Heuson J: Six-year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer 62: 2501–2506, 1988

    Google Scholar 

  31. Wieson RE: Surgical management of locally advanced and recurrent breast cancer. Cancer 53: 752–757, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institutions of Parma, Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy

    Giorgio Cocconi, Guido Ceci, Beatrice Di Blasio, Vincenzo De Lisi & Rodolfo Passalacqua

  2. Institutions of Reggio Emilia, Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy

    Giancarlo Bisagni, Alvise Zadro, Corrado Boni & Luisa Savoldi

  3. Institutions of Vicenza, Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy

    Paolo Morandi

Authors
  1. Giorgio Cocconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giancarlo Bisagni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guido Ceci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Beatrice Di Blasio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincenzo De Lisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rodolfo Passalacqua
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alvise Zadro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Corrado Boni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paolo Morandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Luisa Savoldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cocconi, G., Bisagni, G., Ceci, G. et al. Three new active cisplatin‐containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial. Breast Cancer Res Treat 56, 123–130 (1999). https://doi.org/10.1023/A:1006246012448

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006246012448

Search

Navigation